A Study of MIL62 in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)

NCT05314010 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

102

Enrollment

INDUSTRY

Sponsor class

Conditions

Neuromyelitis Optica Spectrum Disorder

Interventions

DRUG: MIL62
OTHER: Placebo

Sponsor

Beijing Mabworks Biotech Co., Ltd.